What DNASense does

DNASense, founded in 2014 in Aalborg, Denmark, is a microbial analysis company built on DNA sequencing that delivers microbiome and multi-omics research services to academic, clinical, and commercial customers. Following its merger with Clinical Microbiomics, CosmosID, and MS-Omics into the consolidated entity Cmbio, DNASense operates as part of a platform-plus-services organization with regional headquarters in Copenhagen and Germantown, Maryland, and claimed reach across the US, EU, and APAC.

The company's underlying technology is an integrated multi-omics platform spanning shotgun and long-read metagenomics, metabolomics, metatranscriptomics and transcriptomics, proteomics and metaproteomics, marker gene and 16S analysis, plus the cloud-based Cosmos-HUB bioinformatics platform. Service offerings are organized around human health (gut, vaginal, oral, skin, infant, neurology, immuno-oncology, infectious disease/AMR, clinical trials), animal and environmental health (eDNA, AMR surveillance, agriculture, aquaculture, wastewater, soil), and a bioinformatics layer that includes biostatistics, integrative multi-omics, strain tracking and engraftment, and machine learning/AI services.

DNASense monetizes through quote-based, multi-year professional services engagements — laboratory sequencing, custom kitting, and bioinformatics support — alongside a self-serve software channel via Cosmos-HUB. Go-to-market is sales-led with content marketing (insights blog, publications, case studies, webinars) feeding top-of-funnel awareness and direct scientist engagement closing mid- and bottom-of-funnel deals. Marquee relationships include MD Anderson Cancer Center, Brigham and Women's Hospital, Microbiome Labs (co-development), and Resilient Biotics. No revenue, funding, or ownership disclosures are available.

Name

DNASense

Legal name

DNASense

Website

https://dnasense.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

DNASense is a Danish DNA-sequencing-based microbial analysis company that, through its merger into Cmbio, provides end-to-end multi-omics research services and the Cosmos-HUB bioinformatics platform to academic, clinical, and science-driven commercial customers worldwide.

Ownership category

akta.pro rank

Product category

Microbiome and Multi-Omics Research Services

NAICS

Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Microbiome & Metagenomics Services (HLAGANAH)

akta.pro secondary industries

Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI), Microbiome Analytics, Sequencing & Bioinformatics Platforms (HLAAAFAI), Bioinformatics & Multi-omics Analysis Software (HLAGAJAD), Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF)

Keywords

• Microbiome research services
• Multi-omics analysis
• DNA sequencing services
• Bioinformatics platforms
• Microbial analysis

Headquarters

HQ city

Aalborg

HQ country

Denmark

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Laboratory Services: Providing multi-omics sequencing and analysis services to researchers and science-driven companies

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

DNASense provides end-to-end microbiome and multi-omics research services built on DNA sequencing, including shotgun and long-read metagenomics, microbial strain characterization, metabolomics, metatranscriptomics, and proteomics. The company complements laboratory services with the Cosmos-HUB cloud-based bioinformatics platform and AI-driven data analysis for researchers and science-driven companies in human health, animal health, and environmental applications.

Product overview

Cmbio is a multiomics research services company formed through the fusion of Clinical Microbiomics, CosmosID, DNASense, and MS-Omics. The company operates as a platform-plus-services model, offering end-to-end microbiome research services including: Cosmos-Hub (cloud-based bioinformatics platform for data analysis), shotgun and long-read metagenomics sequencing, microbial strain characterization, metabolomics, metatranscriptomics/transcriptomics, proteomics, biostatistics, integrative systems biology and multi-omics integration, strain tracking, machine learning/AI services, and sampling kits. Services span human health (gut, vaginal, oral, skin, infant microbiome; neurology/mental health; cancer/immuno-oncology; infectious diseases), animal health (aquaculture, agriculture, companion animals), and environmental health (eDNA metabarcoding, wastewater, soil health, production safety).

Differentiator

Problem solved

Functional benefit

Products and services

• Cosmos-HUB Cloud-based bioinformatics platform for microbiome data analysis used by research teams to conduct their own bioinformatic and analytic support for clinical and research questions.
• Shotgun Metagenomics Untargeted metagenomic sequencing service that sequences all DNA in a sample to provide high-resolution microbiome analysis across multiple species in complex microbial communities, enabling precise detection of microbial species, functional potential, antimicrobial resistance, and virulence factors.
• Long-Read Metagenomics Long-read sequencing service for building complete microbial genomes and achieving comprehensive taxonomic and functional analysis.
• Microbial Strain Characterization Fast and affordable microbial strain characterization services to explore microbial diversity, functionality, and applications with regulatory report generation.
• Marker Gene Analysis Sequencing service for analyzing specific marker genes in microbial communities.
• Microbiome Profiling Service for profiling the taxonomic composition of microbial communities.
• Absolute Abundance Quantitative microbiome profiling service for measuring the absolute abundance of microbial taxa.
• Direct-to-Consumer Testing Consumer-facing microbiome testing services that provide personalized health insights.
• Metabolomics Services Comprehensive metabolomics services including both untargeted and targeted metabolomics analyses, integrated with metagenomics and other omics data to reveal functional potential and health outcomes.
• Metatranscriptomics and Transcriptomics Services RNA sequencing services for gene expression profiling, active metabolic pathway discovery, and understanding microbial responses under various conditions.
• Proteomics Services Protein analysis services supporting microbiome research.
• Metaproteomics Service for analyzing protein expression in complex microbial communities.
• Bacterial Genome Sequencing 16S rRNA sequencing service for accurate bacterial identification.
• Sampling Kits and Project Handling Custom kits and project handling for efficient microbiome sample collection, preservation, and transport, tailored to study needs and global logistics.
• Biostatistics Statistical analysis services for microbiome and multi-omics research data.
• Integrative Systems Biology and Multi-omics Services Integrative analysis combining multi-omics data (metagenomics, metabolomics, transcriptomics, proteomics, epigenomics) with advanced bioinformatics to deliver actionable insights.
• Strain Tracking and Engraftment Service for tracking microbial strains and monitoring engraftment in microbiome studies.
• Machine Learning and AI Services AI-powered bioinformatics services for analyzing complex microbiome and multi-omics data.

Quantifiable outcome

• Minimizing false positives through robust pipelines and quality controls
• +1 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• CosmosIDcoreStrategic or Co-development PartnerCosmosID is one of the four entities (along with Clinical Microbiomics, DNASense, and MS-Omics) that fused to form Cmbio, creating a comprehensive multi-omics research platform. CosmosID contributed its microbiome analysis expertise and Cosmos-HUB bioinformatics platform.

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• CosmosID: CosmosID is one of the four entities that merged to form Cmbio, and its Cosmos-HUB bioinformatics platform is now a core Cmbio asset. As a historical independent, it was a direct competitor in microbiome analytics and bioinformatics software.
• Zymo Research: Zymo Research provides both microbiome kits/consumables and a microbiome sequencing services arm (ZymoBIOMICS), competing directly with Cmbio on sample collection, sequencing, and bioinformatics. Overlapping product/service model and customer segments.
• Clinical Microbiomics: Clinical Microbiomics (now part of Cmbio) was a direct peer in clinical microbiome sequencing and bioinformatics services, especially for pharma and translational research clients. Pre-merger overlap with DNASense in human health microbiome work.
• RTL Genomics: RTL Genomics (a LGC Group company) provides next-generation sequencing and bioinformatics services for microbiome, environmental, and agricultural research. Directly comparable specialty lab services model and end markets.
• MR DNA: MR DNA (Molecular Research LP) is a contract genomics lab offering 16S, shotgun metagenomics, and bioinformatics for environmental and human microbiome studies. Competes with Cmbio on price-sensitive academic and environmental microbiome projects.
• Diversigen (Eurofins): Diversigen, now part of Eurofins, is one of the closest direct competitors, offering shotgun metagenomics, 16S, and targeted microbiome sequencing services to academic and pharma clients globally. Highly comparable services portfolio and customer base to DNASense/Cmbio.
• MS-Omics: MS-Omics (now part of Cmbio) specialized in mass spectrometry-based metabolomics and proteomics services. Pre-merger it was a direct peer in the metabolomics leg of Cmbio's multi-omics offering.

Emerging players

• Second Genome: Second Genome applies microbiome sciences to drug discovery, with both discovery services and therapeutic programs. Comparable to Cmbio's translational microbiome services business, though it sits further down the value chain toward therapeutics.
• DNAnexus: DNAnexus provides cloud-based bioinformatics platforms for multi-omics data analysis, including microbiome and clinical genomics. Comparable to Cosmos-HUB as a cloud bioinformatics layer serving research and clinical customers.

Broad incumbents

• Qiagen (CLC Bio): Qiagen offers broad bioinformatics platforms (CLC Genomics Workbench) and microbiome sample-to-insight workflows that overlap with Cosmos-HUB. Larger incumbent with broader portfolio but less specialized in pure microbiome services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/dnasense-aps

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DNASense